Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Files An 8-K Regulation FD Disclosure

Item 7.01

The Company issued a press release entitled Xtant Medical Sets
Annual Meeting and Record Dates which is attached as Exhibit 99.1
and incorporated herein.

The information in this Item 7.01 and the document attached as
Exhibit 99.1 are being furnished and shall not be deemed filed
for purposes of Section 18 of the Securities and Exchange Act of
1934, as amended (the Exchange Act), nor otherwise subject
to the liabilities of that section, nor incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.

(d)Exhibits.

About Xtant Medical Holdings, Inc. (NYSEMKT:XTNT)

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.

Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Recent Trading Information

Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) closed its last trading session down -0.025 at 0.490 with 408,499 shares trading hands.